Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.

ABSTRACT:

Background

Neoadjuvant chemotherapy with dual-targeted therapy is the standard treatment for human epidermal growth factor 2 (HER2)-positive breast cancer. Although the dual-targeted therapy has significantly improved the pathological complete response (pCR) rate, further investigation is needed to identify biomarkers that predict the response to neoadjuvant therapy.

Methods

This retrospective study analyzed 353 patients with HER2-positive breast invasive ductal carcinoma. The correlation between clinicopathological factors and pCR rate was evaluated. A nomogram was constructed based on the results of the multivariate logistic regression analysis to predict the probability of pCR.

Results

The breast pCR (b-pCR) rate was 56.1% (198/353) and the total pCR (t-pCR) rate w

SUBMITTER: Yang ZJ 

PROVIDER: S-EPMC10811850 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature